<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3470">
  <stage>Registered</stage>
  <submitdate>21/02/2012</submitdate>
  <approvaldate>21/02/2012</approvaldate>
  <nctid>NCT01541865</nctid>
  <trial_identification>
    <studytitle>Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter</studytitle>
    <scientifictitle>Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter (REDUCE-HTN) - POST MARKET APPROVAL CLINICAL SURVEILLANCE STUDY</scientifictitle>
    <utrn />
    <trialacronym>REDUCE-HTN</trialacronym>
    <secondaryid>CR002-020</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Renal Denervation

Other: Renal Denvervation - All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.


Treatment: devices: Renal Denervation
percutaneous renal denervation using the Vessix RF balloon catheter

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by Office-based Blood Pressure Assessment - Change in systolic and diastolic blood pressure at six (6) months as measured by office-based blood pressure assessment following therapeutic renal denervation compared to baseline. Office blood pressure will be measured using a validated electronic device according to a standardized procedure. .</outcome>
      <timepoint>Baseline and 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by 24-hour Ambulatory Blood Pressure - Change in systolic and diastolic blood pressure at six (6) months as measured by 24-hour ambulatory blood pressure monitoring (ABPM) following therapeutic renal denervation compared to baseline using a validated ABPM device.</outcome>
      <timepoint>Baseline and 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Absence of Flow Limiting Stenosis in the Renal Artery - Absence of flow limiting stenosis in the renal artery at six (6) months follow up time point as measured by renal duplex ultrasound</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Renal Artery Dissection or Perforation During the Procedure That Requires Stenting or Surgery</outcome>
      <timepoint>Duration of the procedure (average of 65 minutes)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Renal Artery Infarction or Embolus</outcome>
      <timepoint>Duration of the procedure (average of 65 minutes)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cerebrovascular Accident (CVA) at Time of Procedure</outcome>
      <timepoint>Duration of the procedure (average of 65 minutes)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction at Time of Procedure</outcome>
      <timepoint>Duration of the procedure (average of 65 minutes)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sudden Cardiac Death at Time of Procedure</outcome>
      <timepoint>Duration of the procedure (average of 65 minutes)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Angiographically-documented Renal Stenosis Requiring an Intervention</outcome>
      <timepoint>2 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chronic Symptomatic Orthostatic Hypotension</outcome>
      <timepoint>2 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hypertensive Emergency Necessitating Hospital Admission (Unrelated to Medication and/or Non-compliance)</outcome>
      <timepoint>2 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in Estimated Glomerular Filtration Rate (eGFR) &gt;25%</outcome>
      <timepoint>2 Years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subjects who have provided written informed consent;

          2. Subjects who are = 18 years and = 75 years of age;

          3. Subjects who have Systolic Blood Pressure (SBP) = 160 mm Hg based on an average of
             three (3) office-based blood pressure readings (seated) measured according to
             protocol;

          4. Subjects with = 3 anti-hypertensive drugs at maximally tolerated doses with stable
             regimen for at least 2 weeks prior to enrollment

          5. Subjects with a estimated glomerular filtration rate (eGFR) = 45 ml/min/1.73m^2;

          6. Suitable renal artery anatomy

          7. Subjects who are willing and able to comply with all study procedures.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subjects with known/diagnosed secondary hypertension;

          2. Subjects who are contraindicated for anticoagulation medications (heparin, aspirin,
             Angiomax, etc.), analgesic medications (morphine, fentanyl, etc.), anxiolytic
             medications (alprazolam, lorazepam, diazepam, etc.) or other medications required for
             an interventional procedure;

          3. Subjects with known bleeding or hyper-coagulation disorders;

          4. Subjects who have type 1 diabetes mellitus;

          5. Subjects who have experienced a myocardial infarction, unstable angina pectoris,
             uncompensated heart failure, or a cerebrovascular accident within six (6) months prior
             to the screening visit, or have widespread atherosclerosis, with documented
             intravascular thrombosis or unstable plaques;

          6. Subjects who have planned percutaneous vascular or surgical intervention for any
             reason within the next 6 months;

          7. Subjects who have hemodynamically significant valvular heart disease for which
             reduction of blood pressure would be considered hazardous;

          8. Subjects who have an implantable cardioverter defibrillator, pacemaker, or clinically
             significant abnormal electrocardiogram

          9. Subjects who have any serious medical condition, which in the opinion of the
             investigator, may adversely affect patient safety or the efficacy of the procedure in
             the study (i.e., patients with clinically significant peripheral vascular disease,
             abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, hemophilia, or
             significant anemia);

         10. Subjects who are pregnant, nursing or planning to become pregnant;

         11. Subjects who have a known, unresolved history of drug use or alcohol abuse/dependency;

         12. Subjects who are currently enrolled in any investigational study wherein patient
             participation has not been completed;

         13. Subjects who, for any reason, may not be able to understand or comply with
             instructions;

         14. Subjects who are contraindicated for intravascular contrast material;

         15. Subjects who are currently taking estrogen or any estrogen-like compound.

         16. Subjects who have had a prior renal denervation procedure

         17. Subjects with prior intervention to right or left renal artery;

         18. Subjects with = 30% renal artery stenosis

         19. Subjects with severe femoral, renal, iliac or aortic calcification that may cause a
             potential complication at the time of the procedure;

         20. Subjects in which the physician is unable to safely cannulate the renal artery;

         21. Subjects in which the physician is unable to percutaneously access the femoral artery;

         22. Subjects with one kidney.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>146</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>St. Vincent's Hospital - Sydney</hospital>
    <hospital>The Prince Charles Hospital, Cardiology Clinical Research Centre - Brisbane</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Monash Cardiovascular Research Centre (Monash Heart) - Clayton</hospital>
    <postcode>2010 - Sydney</postcode>
    <postcode>4032 - Brisbane</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3168 - Clayton</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Berka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Soden/Taunus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg/Saar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Münich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boston Scientific Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The Study objective is to assess the performance of the Vessix V2 Renal Denervation System
      for the treatment of uncontrolled hypertension using an innovative percutaneous Radio
      Frequency (RF) balloon catheter renal denervation device.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01541865</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Horst Sievert, M.D.</name>
      <address>CardioVascular Center Frankfurt, Germany</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>